14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
RYOJ vs NSRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Nasus Pharma Ltd. (NSRX) captures the overall head-to-head institutional edge over rYojbaba Co., Ltd. Common Shares (RYOJ) on higher Unified Composite conviction (45.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 4–3 (led by composite factor balance), while RYOJ wins 5–0 across the 6-pillar growth and valuation breakdown. RYOJ trades at $2.23 (N/M Forward P/E, -8.1% operating margin) versus NSRX at $2.55 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: NSRX earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. RYOJ 42.9/100 HOLD) and 1.00β · 69% Vol risk profile, whereas RYOJ leads top-line expansion (-34.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: RYOJ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3); meanwhile NSRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RYOJ vs NSRX. Trailing 12-month operating profitability (RYOJ -8.1% vs NSRX 0.0%) and valuation multiples (RYOJ N/M vs NSRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $31.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RYOJ vs NSRX Key Questions & Quantitative Answers
As of Nov 19, 2026, Nasus Pharma Ltd. (NSRX) captures the overall head-to-head institutional edge over rYojbaba Co., Ltd. Common Shares (RYOJ) on higher Unified Composite conviction (45.4/100 HOLD vs. 42.9/100 HOLD) after splitting the core matrix 4–3 (led by composite factor balance), while RYOJ wins 5–0 across the 6-pillar growth and valuation breakdown. RYOJ trades at $2.23 (N/M Forward P/E, -8.1% operating margin) versus NSRX at $2.55 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NSRX earns the overall head-to-head edge with a stronger Unified Composite Score (45.4/100 HOLD vs. RYOJ 42.9/100 HOLD) and 1.00β · 69% Vol risk profile, whereas RYOJ leads top-line expansion (-34.3% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RYOJ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.3); meanwhile NSRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RYOJ leads the Growth & Scale pillar: RYOJ posts -34.3% YoY revenue growth and +11.8% YoY earnings growth on $9.3M TTM revenue (26.6% gross margin, -8.1% operating margin), compared with NSRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RYOJ generates $9.3M in USD-normalized revenue versus N/A for NSRX. In operating R&D and SG&A reinvestment, RYOJ deploys 34.7% of Rev ($3.2M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NSRX.
RYOJ screens cheaper on headline valuation multiples. RYOJ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.8x EV/Revenue (-0.6% EBITDA margin), whereas NSRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RYOJ (2.8% ROE) versus NSRX (-316.0% ROE) capital efficiency.
In options market volatility and institutional positioning, RYOJ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 92% Vol realized risk). By comparison, NSRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.00β · 69% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.